FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results Meeting Abstract
| Authors: | Naing, A.; Rosen, L.; Camidge, R. D.; Khalil, D.; Davies, J.; Miles, D.; Patel, M.; Cockle, P.; Champion, B.; Krige, D.; Lillie, T. |
| Abstract Title: | FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S853 |
| End Page: | S854 |
| Language: | English |
| ACCESSION: | WOS:000700527702029 |
| DOI: | 10.1016/j.annonc.2021.08.1395 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #1011P -- Source: Wos |
